Imfinzi

Despite Imfinzi, US accelerated approvals surge
Despite Imfinzi, US accelerated approvals surge
EP Vantage
FDA
accelerated approvals
Imfinzi
AstraZeneca
Flag link:
AZ withdraws Imfinzi in US bladder cancer use after trial failure
AZ withdraws Imfinzi in US bladder cancer use after trial failure
Pharmaforum
AstraZeneca
Imfinzi
bladder cancer
metastatic bladder cancer
clinical trials
Flag link:
AstraZeneca's Imfinzi Fails To Prolong Survival In Late-Stage Head And Neck Cancer Study
AstraZeneca's Imfinzi Fails To Prolong Survival In Late-Stage Head And Neck Cancer Study
Benzinga
AstraZeneca
head and neck cancer
Imfinzi
clinical trials
Flag link:
Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China
Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China
Fierce Pharma
Merck
Bristol-Myers Squibb
AstraZeneca
Roche
Keytruda
Opdivo
Imfinzi
Tecentriq
China
PD-1 inhibitors
Flag link:
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
Fierce Pharma
immuno-oncology
checkpoint inhibitors
Merck
Bristol-Meyers Squibb
COVID-19
Keytruda
Opidvo
Yervoy
Genentech
Tecentriq
AstraZeneca
Imfinzi
Flag link:
ASCO: Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab?
ASCO: Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab?
Fierce Pharma
AstraZeneca
ASCO 2020
clinical trials
tremelimumab
liver cancer
Imfinzi
Flag link:
AstraZeneca's Imfinzi gets FDA nod to target small-cell lung cancer
AstraZeneca's Imfinzi gets FDA nod to target small-cell lung cancer
Reuters
AstraZeneca
FDA
Imfinzi
lung cancer
Small-Cell Lung Cancer
Flag link:
Go or no go? Covid-19 upstages US regulatory decisions
Go or no go? Covid-19 upstages US regulatory decisions
EP Vantage
FDA
regulatory
Bristol-Myers Squibb
ozanimod
Esteve
E-58425
Fabre-Kramer
AstraZeneca
Imfinzi
Astellas
Vesicare
AbbVie
Neurocrine
Orlissa
Sanofi
MenQuadfi
opicapone
Acceleron
Reblozyl
Flag link:
AstraZeneca’s Combination Treatment for HCC Snags Orphan Drug Designation
AstraZeneca’s Combination Treatment for HCC Snags Orphan Drug Designation
BioSpace
AstraZeneca
Imfinzi
orphan drugs
FDA
hepatocellular carcinoma
Flag link:
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
Xconomy
WCLC
lung cancer
KRAS
AMG 510
Amgen
RET
Merck
Keytruda
AstraZeneca
Imfinzi
Blueprint Medicines
Eli Lilly
Flag link:
PhIII lung cancer data signals potential approval for AstraZeneca's Imfinzi
PhIII lung cancer data signals potential approval for AstraZeneca's Imfinzi
Endpoints
AstraZeneca
clinical trials
Imfinzi
Small-Cell Lung Cancer
Flag link:
AstraZeneca Imfinzi combination fails advanced lung cancer study
AstraZeneca Imfinzi combination fails advanced lung cancer study
Yahoo/Reuters
AstraZeneca
Imfinzi
advanced non-small cell lung cancer
tremelimumab
Flag link:
AstraZeneca’s Imfinzi gets FDA orphan drug status for small cell lung cancer
AstraZeneca’s Imfinzi gets FDA orphan drug status for small cell lung cancer
Pharmaceutical Business Review
AstraZeneca
Imfinzi
FDA
small cell lung cancer
orphan drugs
Flag link:
AstraZeneca Has Dazzled in Recent Cancer Trials, but Faces Stiff Competition
AstraZeneca Has Dazzled in Recent Cancer Trials, but Faces Stiff Competition
BioSpace
AstraZeneca
clinical trials
Imfinzi
extensive-stage small cell lung cancer
Calquence
CLL
Flag link:
AZ’s Imfinzi on target in small cell lung cancer, sets up Roche rivalry
AZ’s Imfinzi on target in small cell lung cancer, sets up Roche rivalry
Pharmaforum
AstraZeneca
Imfinzi
extensive-stage small cell lung cancer
Roche
Tecentriq
Flag link:
Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC
Imfinzi demonstrates overall survival at three years in unresectable stage III NSCLC
Pharmaceutical Business Review
AstraZeneca
Imfinzi
ASCO 2019
non-small cell lung cancer
Flag link:
AstraZeneca's Imfinzi gets a lift in lung cancer from England's cost watchdogs
AstraZeneca's Imfinzi gets a lift in lung cancer from England's cost watchdogs
Fierce Pharma
AstraZeneca
Imfinzi
lung cancer
NICE
UK
Flag link:
AZ begins liver cancer immunotherapy tie-up with AVEO
AZ begins liver cancer immunotherapy tie-up with AVEO
Pharmaforum
AstraZeneca
Aveo Oncology
cancer immunotherapy
Imfinzi
Fotivda
hepatocellular carcinoma
Flag link:
AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer
AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer
Fierce Pharma
AstraZeneca
Imfinzi
head and neck cancer
clinical trials
Flag link:
AstraZeneca Shows It Can Still Take Some Knocks
AstraZeneca Shows It Can Still Take Some Knocks
Yahoo/Bloomberg
AstraZeneca
Imfinzi
Flag link:

Pages